search
Back to results

Study of Quadrivalent Influenza Vaccine Among Adults

Primary Purpose

Influenza

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative
Investigational Trivalent Inactivated Influenza Vaccine, No Preservative
Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
Sponsored by
Sanofi Pasteur, a Sanofi Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Influenza focused on measuring Influenza, Quadrivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine, Influenza viruses

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria:

  • Subject is 18 years of age or older on the day of inclusion.
  • Informed consent form (ICF) has been signed and dated.
  • Able to attend all scheduled visits and to comply with all trial procedures.
  • For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks post-vaccination.

Exclusion criteria:

  • Known pregnancy, or a positive urine pregnancy test.
  • Currently breastfeeding a child.
  • History of serious adverse reaction to any influenza vaccine.
  • Receipt of any vaccine in the 4 weeks preceding the trial vaccination.
  • Planned receipt of any vaccine between Visit 1 and Visit 2.
  • Participation in another interventional clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first study vaccination or during the course of the study.
  • Receipt of any influenza vaccine since 01 August 2010 (including 2009 H1N1 monovalent vaccine).
  • Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances.
  • Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response.
  • Thrombocytopenia, bleeding disorder, or receipt of anticoagulants contraindicating intramuscular vaccination.
  • Any condition that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with the evaluation of the vaccine.
  • Personal history of Guillain-Barré Syndrome (GBS).
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • Any chronic illness that, in the opinion of the Investigator, is not well controlled or that may interfere with trial conduct or completion or with assessment of adverse events.
  • Known seropositivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Current alcohol or drug use that, in the opinion of the Investigator, might interfere with the ability to comply with trial procedures.
  • Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Group 1: Investigational Quadrivalent Influenza Vaccine

Group 2: Investigational Trivalent Influenza Vaccine

Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine

Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine

Arm Description

Participants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine

Participants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine

Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine

Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine

Outcomes

Primary Outcome Measures

Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines With Corresponding B Strain in Participants Aged 65 Years and Older.
Immunogenicity outcomes were assessed in serum samples by hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as <10.
Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or After Trivalent Influenza Vaccines Without Corresponding B Strain in Participants Aged 65 Years and Older.
Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as <10.
Geometric Mean Titers Against the Influenza Virus Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines (TIV) in Participants Aged 18 Years or Older
Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as <10.

Secondary Outcome Measures

Full Information

First Posted
October 8, 2010
Last Updated
September 13, 2013
Sponsor
Sanofi Pasteur, a Sanofi Company
search

1. Study Identification

Unique Protocol Identification Number
NCT01218646
Brief Title
Study of Quadrivalent Influenza Vaccine Among Adults
Official Title
Safety and Immunogenicity Trial Among Adults Administered Quadrivalent Influenza Vaccine
Study Type
Interventional

2. Study Status

Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
October 2010 (undefined)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
April 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi Pasteur, a Sanofi Company

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain, and the investigational TIV containing the alternate B strain in adult subjects. Primary Objective: To demonstrate non-inferiority of antibody responses to QIV compared with licensed 2010-2011 TIV (containing the primary B strain) and investigational TIV (containing the alternate B strain) as assessed by geometric mean titer (GMT) ratios for each of the four virus strains separately among subjects 65 years of age and older Observational Objective: To describe the safety profiles of TIV among subjects 18 years of age and older and QIV in subjects 65 years and older, as assessed by solicited injection site and systemic adverse events (AEs) collected for 7 days post-vaccination, unsolicited adverse events collected from 21 days post-vaccination, and adverse events of special interest and serious adverse events (SAEs) collected from Visit 1 to Visit 2.
Detailed Description
All participants will receive a single dose of their assigned vaccine during Visit 1. They will be followed up for safety and immunogenicity through Day 21 post-vaccination (Visit 2)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza
Keywords
Influenza, Quadrivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine, Influenza viruses

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
739 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1: Investigational Quadrivalent Influenza Vaccine
Arm Type
Experimental
Arm Description
Participants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine
Arm Title
Group 2: Investigational Trivalent Influenza Vaccine
Arm Type
Experimental
Arm Description
Participants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine
Arm Title
Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine
Arm Type
Active Comparator
Arm Description
Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
Arm Title
Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine
Arm Type
Active Comparator
Arm Description
Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
Intervention Type
Biological
Intervention Name(s)
Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative
Intervention Description
0.5 mL, Intramuscular
Intervention Type
Biological
Intervention Name(s)
Investigational Trivalent Inactivated Influenza Vaccine, No Preservative
Intervention Description
0.5 mL, Intramuscular
Intervention Type
Biological
Intervention Name(s)
Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
Other Intervention Name(s)
Fluzone®
Intervention Description
0.5 mL, Intramuscular
Intervention Type
Biological
Intervention Name(s)
Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
Other Intervention Name(s)
Fluzone®
Intervention Description
0.5 mL, Intramuscular
Primary Outcome Measure Information:
Title
Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines With Corresponding B Strain in Participants Aged 65 Years and Older.
Description
Immunogenicity outcomes were assessed in serum samples by hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as <10.
Time Frame
Day 21 post-vaccination
Title
Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or After Trivalent Influenza Vaccines Without Corresponding B Strain in Participants Aged 65 Years and Older.
Description
Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as <10.
Time Frame
Day 21 post-vaccination
Title
Geometric Mean Titers Against the Influenza Virus Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines (TIV) in Participants Aged 18 Years or Older
Description
Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as <10.
Time Frame
Day 0 and Day 21 post-vaccination
Other Pre-specified Outcome Measures:
Title
Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines (TIV) With Corresponding B Strains in Participants Aged 65 Years and Older.
Description
Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as < 10. Seroconversion was defined as either a pre-vaccination HAI titer < 1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥ four-fold increase in post-vaccination titer.
Time Frame
Day 21 post-vaccination
Title
Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines Without Corresponding B Strain in Participants Aged 65 Years and Older.
Description
Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as <10. Seroconversion was defined as either a pre-vaccination HAI titer < 1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥ 1:10 and ≥ four-fold increase in post-vaccination titers.
Time Frame
Day 21 post-vaccination
Title
Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines in Participants Aged 18 Years or Older.
Description
Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as <10. Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 1:40 (l/dil)
Time Frame
Day 21 post-vaccination
Title
Seroconversion Against Influenza Virus Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines in Participants Aged 18 Years and Older
Description
Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as <10. Seroconversion was defined as either a pre-vaccination HAI titer <1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥ four-fold increase in post-vaccination titer.
Time Frame
Day 21 post-vaccination
Title
Number of Participants Reporting Solicited Injection Site and Systemic Reactions After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines.
Description
Solicited injection site reactions: Pain, Erythema and Swelling; Solicited systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3 Injection site reactions: Pain - Significant; prevents daily activity; Erythema and Swelling >100 mm. Grade 3 solicited systemic reactions: Fever (Temperature) ≥102.1°F; Headache, Malaise, and Myalgia - Significant; prevents daily activity.
Time Frame
Day 0 up to day 21 post-vaccination

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: Subject is 18 years of age or older on the day of inclusion. Informed consent form (ICF) has been signed and dated. Able to attend all scheduled visits and to comply with all trial procedures. For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks post-vaccination. Exclusion criteria: Known pregnancy, or a positive urine pregnancy test. Currently breastfeeding a child. History of serious adverse reaction to any influenza vaccine. Receipt of any vaccine in the 4 weeks preceding the trial vaccination. Planned receipt of any vaccine between Visit 1 and Visit 2. Participation in another interventional clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first study vaccination or during the course of the study. Receipt of any influenza vaccine since 01 August 2010 (including 2009 H1N1 monovalent vaccine). Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances. Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response. Thrombocytopenia, bleeding disorder, or receipt of anticoagulants contraindicating intramuscular vaccination. Any condition that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with the evaluation of the vaccine. Personal history of Guillain-Barré Syndrome (GBS). Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). Any chronic illness that, in the opinion of the Investigator, is not well controlled or that may interfere with trial conduct or completion or with assessment of adverse events. Known seropositivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily. Current alcohol or drug use that, in the opinion of the Investigator, might interfere with the ability to comply with trial procedures. Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Sanofi Pasteur Inc.
Official's Role
Study Director
Facility Information:
City
Hoover
State/Province
Alabama
ZIP/Postal Code
35216
Country
United States
City
South Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
City
Springfield
State/Province
Missouri
ZIP/Postal Code
65802
Country
United States
City
New York
State/Province
New York
ZIP/Postal Code
10004
Country
United States
City
Rochester
State/Province
New York
ZIP/Postal Code
14609
Country
United States
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45249
Country
United States
City
Allentown
State/Province
Pennsylvania
ZIP/Postal Code
18102
Country
United States
City
Bensalem
State/Province
Pennsylvania
ZIP/Postal Code
19020
Country
United States
City
Warwick
State/Province
Rhode Island
ZIP/Postal Code
02866
Country
United States
City
Mt. Pleasant
State/Province
South Carolina
ZIP/Postal Code
29464
Country
United States
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37212
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.sanofipasteur.com
Description
Related Info

Learn more about this trial

Study of Quadrivalent Influenza Vaccine Among Adults

We'll reach out to this number within 24 hrs